.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Lecanemab is an antibody directed against soluble amyloid-beta protofibrils and was evaluated in a large phase 3 trial involving people with early Alzheimer disease and biomarker-confirmed amyloid pathology. Over 18 months, participants receiving lecanemab had a smaller worsening in Clinical Dementia Rating-Sum of Boxes than those receiving placebo, along with greater reductions in brain amyloid burden and modest advantages on cognitive and functional measures. The trial established that amyloid-targeting treatment can produce a measurable slowing of progression in early symptomatic disease. The benefits were modest rather than restorative, and treatment was associated with infusion reactions and amyloid-related imaging abnormalities, including edema or effusions. These safety issues require careful patient selection, MRI monitoring and counselling. For HCPs, the study signals a new treatment era in Alzheimer disease, but it also changes the practical workflow: diagnosis needs stronger biological confirmation, risk assessment needs to consider factors such as APOE status and cerebrovascular disease, and treatment requires structured safety monitoring. The trial is highly relevant to IANCON's emphasis on dementia diagnostics, biomarkers and emerging disease-modifying therapies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Lecanemab is an antibody directed against soluble amyloid-beta protofibrils and was evaluated in a large phase 3 trial involving people with early Alzheimer disease and biomarker-confirmed amyloid pathology. Over 18 months, participants receiving lecanemab had a smaller worsening in Clinical Dementia Rating-Sum of Boxes than those receiving placebo, along with greater reductions in brain amyloid burden and modest advantages on cognitive and functional measures. The trial established that amyloid-targeting treatment can produce a measurable slowing of progression in early symptomatic disease. The benefits were modest rather than restorative, and treatment was associated with infusion reactions and amyloid-related imaging abnormalities, including edema or effusions. These safety issues require careful patient selection, MRI monitoring and counselling. For HCPs, the study signals a new treatment era in Alzheimer disease, but it also changes the practical workflow: diagnosis needs stronger biological confirmation, risk assessment needs to consider factors such as APOE status and cerebrovascular disease, and treatment requires structured safety monitoring. The trial is highly relevant to IANCON's emphasis on dementia diagnostics, biomarkers and emerging disease-modifying therapies.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
